Biogen Licenses Remedy’s Stroke Drug

19.05.2017 - Biogen has licensed a late-stage stroke drug from Remedy Pharmaceuticals. The US biotech will make an upfront payment of $120 million for Cirara (intravenous glyburide), as well as...